The Incidence of Contrast-induced Acute Kidney Injury in Patients on Dapagliflozin Undergoing Percutaneous Coronary Interventions
Hany Hassan Ebaid, Ahmed Bahaa El Dein Abd El Hafeez, Khaled Emad El Dein El Rabat & Karim Elakabawi · Cardiology and Angiology: An International Journal · 2024
Background: Sodium glucose cotransporter 2 receptor inhibitor (SGLT2i) dapagliflozin protects the renal function of individuals with coronary artery disease (CAD) and reduces incidence of contrast-induced acute kidney injury (CI-AKI) among individuals having percutaneous coronary...
Open access
Research Article
10.9734/ca/2024/v13i4454